drugset / Trial / NCT04776447
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
NaSingle-groupOpen-labelTreatment
Summary
Open-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment (Atezolizumab + Induction chemotherapy (CT) + CT-Radiotherapy) in terms of the Progression Free Survival at 12 months
Timeline
- Start
- 2021-06-16
- Primary completion
- 2026-11-15
- Completion
- 2027-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | — |